Pharmacology · General Anesthesia
Inhalational pharmacokinetics, anesthetic potency, intravenous agents, and preanesthetic medications
Abbreviations: MAC = minimum alveolar concentration · IV = intravenous · QT = QT interval on the electrocardiogram
Inhalational Pharmacokinetics
Key Pharmacokinetic Property
Blood:Gas Partition Coefficients and Induction Speed
| Agent | Blood:Gas Coefficient | Induction Speed | Clinical Notes |
|---|---|---|---|
| Desflurane | ~0.42 (lowest) | Fastest | Pungent — not used for inhalational induction; very rapid emergence |
| Nitrous oxide | ~0.47 | Very fast | Minimum alveolar concentration 104% — cannot produce surgical anesthesia alone |
| Sevoflurane | ~0.65 | Fast | Preferred agent for pediatric inhalational induction; pleasant odor |
| Isoflurane | ~1.4 | Moderate | Standard volatile agent for maintenance; pungent odor limits inhalational induction |
| Halothane | ~2.4 (highest) | Slowest | High hepatotoxicity risk — largely replaced by newer agents |
Rule: Low blood:gas coefficient = low solubility in blood = fast rise in alveolar partial pressure = fast induction. High coefficient = slow induction, slow emergence.
Anesthetic Potency
Minimum Alveolar Concentration
Factors That Decrease MAC
Minimum Alveolar Concentration
Factors That Increase MAC
MAC additivity: 0.5 minimum alveolar concentration isoflurane + 0.5 minimum alveolar concentration nitrous oxide = 1.0 minimum alveolar concentration effect. MAC-awake (return of consciousness) = approximately 0.3–0.4 minimum alveolar concentration.
Intravenous Anesthetic Agents
IV Induction Agent
Propofol
IV Induction Agent
Etomidate
IV Induction Agent
Ketamine
IV Sedation Agent
Dexmedetomidine
Preanesthetic Medications
Drug Classes and Mechanisms
Preanesthetic Medication Summary
| Drug | Mechanism | Primary Use | Key Point |
|---|---|---|---|
| Midazolam | Gamma-aminobutyric acid type A potentiation | Anxiolysis, anterograde amnesia, reduces minimum alveolar concentration | Most widely used preanesthetic sedative |
| Fentanyl | Opioid receptor agonist | Baseline analgesia; blunts laryngoscopy hemodynamic response | Rapid onset IV; risk of respiratory depression |
| Ondansetron | 5-hydroxytryptamine type 3 antagonist | Postoperative nausea and vomiting prophylaxis | Given at end of surgery for early nausea and vomiting |
| Dexamethasone | Glucocorticoid | Postoperative nausea and vomiting prophylaxis | Given at induction (delayed onset) |
| Droperidol | Dopamine D2 antagonist | Postoperative nausea and vomiting prophylaxis | Black box warning: QT prolongation / torsades de pointes |
| Glycopyrrolate | Muscarinic antagonist (quaternary amine) | Antisialagogue; does not cross blood-brain barrier | No central anticholinergic effects (compare atropine) |
| Metoclopramide | Dopamine D2 antagonist + 5-hydroxytryptamine type 4 agonist | Aspiration prophylaxis: empties stomach, increases lower esophageal sphincter tone | Contraindicated in bowel obstruction |
| Sodium citrate | Non-particulate antacid (direct buffer) | Rapid neutralization of gastric acid before induction | Safe if aspirated (non-particulate) |
Suggested References
| Author / Organization | Title | Source |
|---|---|---|
| Katzung BG, ed. | Basic and Clinical Pharmacology. 15th ed. | McGraw-Hill; 2021 |
| Brunton LL, Knollmann BC, eds. | Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed. | McGraw-Hill; 2023 |
| Eger EI 2nd | Anesthetic Uptake and Action | Baltimore: Williams & Wilkins; 1974 |
| Miller RD, ed. | Miller's Anesthesia, 8th ed. Chapters 17, 27 | Philadelphia: Elsevier; 2015 |
| Malviya S, Lerman J | The blood/gas solubilities of sevoflurane, isoflurane, halothane, and serum constituent concentrations in newborns and adults | Anesthesiology. 1990;72(5):793–796 |
| Stoelting RK, Hillier SC | Pharmacology and Physiology in Anesthetic Practice, 4th ed. | Philadelphia: Lippincott Williams & Wilkins; 2006 |
| Apfel CC, et al. | A simplified risk score for predicting postoperative nausea and vomiting | Anesthesiology. 1999;91(3):693–700 |
| Eger EI 2nd | Age, minimum alveolar anesthetic concentration, and minimum alveolar anesthetic concentration-awake | Anesth Analg. 2001;93(4):947–953 |
| Fink BR | Diffusion anoxia | Anesthesiology. 1955;16(4):511–519 |
| Epstein RM, et al. | Influence of the concentration effect on the uptake of anesthetic mixtures: the second gas effect | Anesthesiology. 1964;25:364–371 |
| Eger EI 2nd, Saidman LJ, Brandstater B | Minimum alveolar anesthetic concentration: a standard of anesthetic potency | Anesthesiology. 1965;26:756–763 |
| Gan TJ, et al. | Consensus guidelines for the management of postoperative nausea and vomiting | Anesth Analg. 2014;118(1):85–113 |
| Flood P, Rathmell JP, Shafer SL, eds. | Stoelting's Pharmacology and Physiology in Anesthetic Practice, 5th ed. | Philadelphia: Wolters Kluwer; 2015 |
| Marik PE | Propofol: therapeutic indications and side-effects | Curr Pharm Des. 2004;10(29):3639–3649 |
| White PF, et al. | Pharmacology of ketamine isomers in surgical patients | Anesthesiology. 1980;52(3):231–239 |
| Weerink MAS, et al. | Clinical pharmacokinetics and pharmacodynamics of dexmedetomidine | Clin Pharmacokinet. 2017;56(8):893–913 |